Payment overview · 2025
General Payments
$1,557.39
43 reported records · 5 companies
Healthcare provider profile · identity verified
Jane Nwankwookoye
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · RENTON, WA · NPI 1013574243
Verified facts
What the public records show
CMS Open Payments records show Jane Nwankwookoye received $1,557.39 in general payments during 2025 across 43 reported records.
Janssen Pharmaceuticals, Inc accounted for 72.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna, Invega Trinza, Lybalvi, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lybalvi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Invega Trinza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $1,123.96 | 72.2% | 24 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $182.87 | 11.7% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $167.01 | 10.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.23 | 3.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.32 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $869.62 | 37 |
| Travel and Lodging | $687.77 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $984.18 | 15 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $182.87 | 9 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $182.87 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $167.01 | 7 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $139.78 | 9 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $139.78 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.71 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA TRINZA invega trinza |
2025 | Invega Trinza | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 452 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 373 | 33 |
| Olanzapine | Olanzapine | 349 | 31 |
| Risperidone | Risperidone | 292 | 25 |
| Clozapine | Clozapine | 236 | 12 |
| Divalproex Sodium | Divalproex Sodium | 225 | 21 |
| Benztropine Mesylate | Benztropine Mesylate | 224 | 24 |
| Clonazepam | Clonazepam | 207 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 157 | 32 |
| Sertraline Hcl | Sertraline Hcl | 156 | 18 |
| Mirtazapine | Mirtazapine | 146 | 17 |
| Buspirone Hcl | Buspirone Hcl | 145 | 19 |
| Haloperidol | Haloperidol | 135 | 14 |
| Lorazepam | Lorazepam | 123 | 26 |
| Vraylar | Cariprazine Hcl | 122 | 11 |
| Lamotrigine | Lamotrigine | 120 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 14 |
| Memantine Hcl | Memantine Hcl | 102 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 101 | 25 |
| Aripiprazole | Aripiprazole | 97 | 15 |
| Prazosin Hcl | Prazosin Hcl | 91 | 12 |
| Bupropion Xl | Bupropion Hcl | 84 | suppressed |
| Gabapentin | Gabapentin | 81 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 81 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 78 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 73 | suppressed |
| Amantadine | Amantadine Hcl | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 62 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Paliperidone Er | Paliperidone | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 17 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,557.39 · 43 records | Janssen Pharmaceuticals, Inc | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, REXULTI, SPRAVATO, TRINTELLIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error